SecBot SecBot
DEFA14A ·Filed Mar 17, 2026

OSUR

ORASURE TECHNOLOGIES INC
MIXED
Impact 6/10
Horizonmonths Processed8mo ago SEC0001193125-26-111262
Proxy solicitation materials
Actionable Insight ◆ Mixed

Monitor the outcome of the proxy vote and whether Altai gains board seats. Upcoming FDA decisions on CT/NG and Colli-Pee in 2026 will be critical catalysts. Insider buying and the repurchase program suggest management confidence, but revenue growth has not yet materialized.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$2.90
T+0 close · Mar 17, 2026 · via day close
Latest settled
+44.48%
T+60 · $4.19
Vs SPY
+32.96%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 18 $2.90entry
  2. T+1 · 8mo ago +0.34%α +0.61% · $2.91
  3. T+5 · 8mo ago +8.28%α +8.99% · $3.14
  4. T+20 · 7mo ago +10.69%α +4.64% · $3.21
  5. T+60 · 5mo ago +44.48%α +32.96% · $4.19
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

OraSure Technologies filed a definitive proxy statement (DEFA14A) in response to an activist campaign by Altai Capital, which is pushing for board representation to force a sale of the company. OraSure's management defends its transformation strategy, highlighting upcoming product launches, cost reductions, and a $40 million share buyback, while accusing Altai's founder of seeking personal control rather than shareholder value.

Key Facts

  • OraSure is facing a proxy contest from activist investor Altai Capital, which seeks board representation to push for a sale.
  • The company has rejected Altai's demands, stating it is at a strategic inflection point with key product launches in 2026.
  • OraSure highlights operational progress: 40% workforce reduction, 37% SG&A cost cut since 2022, and ~260 bps gross margin expansion.
  • The company submitted FDA applications for two high-impact STI tests targeting a $2B market.
  • OraSure announced a $40 million share repurchase program and leadership stock purchases to signal confidence.
  • Altai rejected settlement offers, including the appointment of its nominee John Bertrand and a board declassification proposal.

Financial Impact

$40 million share repurchase program announced; no specific revenue or earnings figures provided

dilutioncashshareholder valuecapital allocation

Risk Factors

  • Proxy contest could lead to board instability or strategic disruption.
  • Failure to achieve FDA clearance for key products in 2026 would undermine growth strategy.
  • Revenue growth remains forward-looking with no current financial improvement confirmed.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-111262
Document: 0001193125-26-111262-index-headers.html0001193125-26-111262
Document: 0001193125-26-111262-index.html0001193125-26-111262
Document: 0001193125-26-111262.txt0001193125-26-111262

Track record

20 reports on OSUR

Performance horizon

6 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +39.73% at T+60 after the Mar 13, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago 10-Q/A Neutral 2/10 Entry $3.62 to $3.62 Now $3.60 −0.55% · 0.00% +0.36% vs SPY
  2. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $3.33 to $3.56 Now $3.60 +8.11% ▲ +6.91% +5.59% vs SPY
  3. Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $3.53 to $3.33 Now $3.60 +1.98% ▼ −5.67% −5.30% vs SPY
  4. Nov 2, 202614d ago Press Release Neutral 2/10 Entry $3.46 to $3.53 Now $3.60 +4.20% ▲ +2.17% +1.87% vs SPY
  5. Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $3.94 to $3.46 Now $3.60 −8.63% ▼ −12.31% −11.83% vs SPY
  6. Sep 17, 20268w ago SC 13D Bullish 6/10 Entry $3.56 to $3.69 Now $3.60 +1.12% ▲ +3.65% +2.10% vs SPY
  7. Jul 23, 202616w ago Court Ruling Neutral 3/10 Entry $3.97 to $3.96 Now $3.60 −9.32% ▼ −0.25% −0.27% vs SPY
  8. Jun 12, 202622w ago Institutional Cluster Mixed 4/10 Entry $4.18 to $4.17 Now $3.60 −13.88% ▼ −0.24% −2.00% vs SPY
  9. Jun 3, 202623w ago 8-K Neutral 3/10 Entry $4.17 to $4.04 Now $3.60 −13.67% ▼ −3.12% −0.52% vs SPY
  10. May 6, 202627w ago 8-K Bearish 6/10 Entry $3.13 to $3.06 Now $3.60 −15.02% ▲ +2.24% +3.07% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 17, 2026